JP2023504542A5 - - Google Patents

Info

Publication number
JP2023504542A5
JP2023504542A5 JP2022533451A JP2022533451A JP2023504542A5 JP 2023504542 A5 JP2023504542 A5 JP 2023504542A5 JP 2022533451 A JP2022533451 A JP 2022533451A JP 2022533451 A JP2022533451 A JP 2022533451A JP 2023504542 A5 JP2023504542 A5 JP 2023504542A5
Authority
JP
Japan
Prior art keywords
substituted
compound according
alkyl
unsubstituted
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022533451A
Other languages
English (en)
Japanese (ja)
Other versions
JP7721143B2 (ja
JP2023504542A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063383 external-priority patent/WO2021113690A1/en
Publication of JP2023504542A publication Critical patent/JP2023504542A/ja
Publication of JP2023504542A5 publication Critical patent/JP2023504542A5/ja
Application granted granted Critical
Publication of JP7721143B2 publication Critical patent/JP7721143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022533451A 2019-12-04 2020-12-04 Masp-2阻害剤および使用方法 Active JP7721143B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943622P 2019-12-04 2019-12-04
US62/943,622 2019-12-04
PCT/US2020/063383 WO2021113690A1 (en) 2019-12-04 2020-12-04 Masp-2 inhibitors and methods of use

Publications (3)

Publication Number Publication Date
JP2023504542A JP2023504542A (ja) 2023-02-03
JP2023504542A5 true JP2023504542A5 (cg-RX-API-DMAC7.html) 2023-10-05
JP7721143B2 JP7721143B2 (ja) 2025-08-12

Family

ID=73854995

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533451A Active JP7721143B2 (ja) 2019-12-04 2020-12-04 Masp-2阻害剤および使用方法

Country Status (10)

Country Link
US (1) US11661418B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069678A1 (cg-RX-API-DMAC7.html)
JP (1) JP7721143B2 (cg-RX-API-DMAC7.html)
CN (1) CN115052862A (cg-RX-API-DMAC7.html)
AU (1) AU2020397894B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010881A2 (cg-RX-API-DMAC7.html)
CA (1) CA3159167A1 (cg-RX-API-DMAC7.html)
IL (1) IL293551A (cg-RX-API-DMAC7.html)
WO (1) WO2021113690A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202409281B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Masp-2阻害剤および使用方法
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
TWI867422B (zh) 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN116514772B (zh) * 2022-01-28 2025-09-16 武汉朗来科技发展有限公司 作为masp-2抑制剂的化合物、药物组合物及其制备方法和用途
WO2025207595A1 (en) * 2024-03-25 2025-10-02 Entasis Therapeutics, Inc. Modulators of mannan-binding lectin-associated protease

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
EP1082324A4 (en) 1998-05-26 2002-01-02 Merck & Co Inc IMIDAZOPYRIDINE COMPOUNDS AS THROMBINE INHIBITORS
AU3192500A (en) 1999-03-16 2000-10-04 C & C Research Laboratories Substituted proline derivatives and medicinal compositions containing the same
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
HUP0202191A3 (en) 1999-05-19 2003-02-28 Pharmacia Corp Chicago Substituted polycyclic aryl and heteroaryl pirazinones useful for selective inhibition of the coagulation cascade and pharmaceutical compositions containing them
JP2004516286A (ja) 2000-12-18 2004-06-03 メルク エンド カムパニー インコーポレーテッド ベンジルアミン誘導体およびそれのトロンビン阻害薬としての使用
CA2462647A1 (en) 2001-10-03 2003-04-10 Michael S. South 6-membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
US20140056873A1 (en) 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DE602006010834D1 (de) * 2005-03-16 2010-01-14 Janssen Pharmaceutica Nv Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP3150635A3 (en) 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
PT2861246T (pt) 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
AR091490A1 (es) 2012-06-19 2015-02-11 Bristol Myers Squibb Co Antagonistas de iap
EP2922535B1 (en) 2012-11-20 2021-11-10 Merck Sharp & Dohme Corp. Thrombin inhibitors
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
CN117398458A (zh) 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
CA3010593C (en) 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
US20170253667A1 (en) 2016-01-05 2017-09-07 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
NZ745531A (en) * 2016-03-31 2020-09-25 Omeros Corp Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
US20180105604A1 (en) 2016-10-13 2018-04-19 University Of Leicester Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
TWI818919B (zh) 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
BR112020004800A2 (pt) 2017-09-13 2020-09-24 Amgen Inc. compostos de bisamida ativantes do sarcômero e seus usos
GB201805174D0 (en) * 2018-03-29 2018-05-16 Univ Leeds Innovations Ltd Compounds
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
AU2020395306B2 (en) * 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
JP7699389B2 (ja) * 2019-12-04 2025-06-27 オメロス コーポレーション Masp-2阻害剤および使用方法
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan

Similar Documents

Publication Publication Date Title
RU2483072C2 (ru) Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2011513305A5 (cg-RX-API-DMAC7.html)
JP2020169171A5 (cg-RX-API-DMAC7.html)
JP2021514001A5 (cg-RX-API-DMAC7.html)
JP2022544714A5 (cg-RX-API-DMAC7.html)
JP2011219498A5 (cg-RX-API-DMAC7.html)
JP2023504543A5 (cg-RX-API-DMAC7.html)
JP2016509591A5 (cg-RX-API-DMAC7.html)
JP2018528261A5 (cg-RX-API-DMAC7.html)
JP2007524696A5 (cg-RX-API-DMAC7.html)
JP2020531531A5 (cg-RX-API-DMAC7.html)
JP2008510691A5 (cg-RX-API-DMAC7.html)
JP2006515858A5 (cg-RX-API-DMAC7.html)
JP2010530372A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2013532652A5 (cg-RX-API-DMAC7.html)
JP2022525069A5 (cg-RX-API-DMAC7.html)
JP2020531526A5 (cg-RX-API-DMAC7.html)
JP2021535174A5 (cg-RX-API-DMAC7.html)
JP2019527724A5 (cg-RX-API-DMAC7.html)
JP2024516033A5 (cg-RX-API-DMAC7.html)
RU2005111589A (ru) Производные 1-пиридин-4-илмочевины
JP2022501334A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)